Event
OSCO Presents Best of ASCO
The Oklahoma Society of Clinical Oncology, Inc.
The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2025 In-Person Fall Conference, which will be an officially licensed BEST OF ASCO event held at Andrews Academic Tower on Saturday, September 27th. his conference will highlight the foremost research and strategies in oncology that were presented by speakers at the 2025 American Society of Clinical Oncology’s (ASCO®) Annual Meeting. This conference is designed to update the educational needs of Hematologists/Oncologists, Nurses, Pharmacists, Physician Assistants, and other healthcare professionals specializing in oncology. This activity will be approved for continuing education credits for physicians, pharmacists, and nurses. There is no fee for this conference, but registration is required.
This activity will be approved for 4 hours of continuing education credits for physicians, nurses, and pharmacists. There is no fee for this conference, but registration is required.
BEST OF ASCO® is an officially licensed program of the American Society of Clinical Oncology, Inc. (ASCO®).
This conference is jointly provided by the Postgraduate Institute for Medicine and the Oklahoma Society of Clinical Oncology, Inc.
- For more information contact OSCO Executive Director Kathleen Musson by e-mail to kmusson@nextwavegroup.net
- For Corporate Member registration, please contact Kathleen directly at the email above.
- All trainees to participate in our Trainee Research Abstract competition which will be conducted on September 27th, 2025, at the Andrews Academic Tower, Oklahoma City, OK. Click here to find out more about the competition.
Online Registration is now closed. Please come to the event and register on site.
Show Agenda-
7:00 amExhibitor Set up
-
7:30 amRegistration & Continental Breakfast Opens
-
8:00 - 8:15 amWelcome Remarks – Adanma Ayanambakkam, MD, OSCO President Elect
-
8:15 am – 9:00 amUpdates in Gastrointestinal Oncology
Elad Sharon, MD, MPH
Updates in Gastrointestinal Oncology
Clinical and Translational Director of the Immunotherapy Toxicity Program Dana-Farber Cancer Institute, Faculty, Harvard Medical School, Boston, MA
-
9:15 am – 10:15 amUpdates in Myeloma
Jens Hillengass, MD, PhD
Updates in Myeloma
Chief of Myeloma and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, New York
-
10:15–10:45 AMBreak for exhibits/refreshments, view abstracts
-
10:45 am – 11:00 amOral Presentation by Resident Abstract Winner
-
11:00 am – 12:00 pmUpdates in GU Oncology
Tian Zhang, MD, MHS, FASCO
Updates in GU Oncology
Associate Director for Clinical Research , Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
-
12:00 -1:00 PMUpdates in Thoracic Oncology
Abdul Rafeh Naqash, MD
Updates in Thoracic Oncology
OU Health Stephenson Cancer Center — Oklahoma TSET Phase I Program
-
1:00 PMAnnouncement of Resident Abstract Award Winners
-
1:15 pmAdjournment